A real-world evidence study evaluating quality of life parameters following treatment with Otrivine (xylometazoline hydrochloride)

The Virtual Clinical Trials Centre0 个研究点目标入组 136 人开始时间: 2022年8月16日最近更新: 2024年6月3日

适应症

试验速览

暂无简介。

•1. Aged 18 years old and over at the signing of the informed consent
•2. Reporting nasal congestion and at least one other common cold symptom among runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired
•3. Reporting a minimum score of 5 (moderate) for plugged nose associated with common cold symptoms and at least one other symptom of the common cold (at least mild score of 3) as per the WURSS-21 questionnaire at screening and within 24 hours of study product receipt
•4. Initiation of cold symptoms within 24 hours of initiation of screening

•1. Allergic to xylometazoline hydrochloride or any of the other ingredients in the spray
•2. Individuals who have had recent neurosurgery or self-report narrow-angle glaucoma, chronic nasal inflammation with very dry nasal passages (rhinitis sicca or atrophic rhinitis), an enlarged prostate gland, a rare tumour of the adrenal gland that produces high amounts of adrenaline and noradrenaline (pheochromocytoma)
•3. Taking monoamine oxidase inhibitors (MAOIs) or have stopped taking them in the last 14 days
•4. Individuals who are pregnant, lactating, or plan to be pregnant or lactating during
•the course of the study
•5. Is currently using or has used a nasal decongestant (i.e. adrenergic, steroids) within the last 7 days (or for more than 7 days) prior to initiating study treatment

发起方

The Virtual Clinical Trials Centre